Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811)

Description of Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811)

Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811): A Potent Antibody Targeting a Key Therapeutic Receptor

Introduction

CD198, also known as CCR8, is a chemokine receptor that plays a crucial role in the immune system by regulating the migration and activation of immune cells. It is expressed on a variety of immune cells, including T cells, B cells, and dendritic cells, and has been implicated in various inflammatory and autoimmune diseases. As such, CD198 has emerged as a promising therapeutic target, and the development of specific antibodies against this receptor has gained significant attention. In this article, we will discuss the structure, activity, and potential applications of Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811), a novel antibody with high specificity and potency against CD198.

Structure of Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811)

Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811) is a monoclonal antibody that specifically binds to the extracellular domain of CD198. It is a fully human IgG1 antibody, which means it is less likely to cause immune reactions in patients. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains are made up of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains have two constant domains (CL and CL1) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for binding to CD198, making Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811) a highly specific antibody.

Activity of Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811)

Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811) has been extensively characterized for its activity against CD198. In vitro studies have shown that the antibody effectively blocks the binding of the natural ligand of CD198, CCL1, to the receptor, indicating its ability to inhibit the signaling pathway of CD198. Additionally, the antibody has been shown to induce internalization and degradation of CD198, further reducing its activity. In vivo studies in animal models have also demonstrated the efficacy of Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811) in reducing inflammation and autoimmune responses by targeting CD198.

Application of Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811)

Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811) has potential applications in various inflammatory and autoimmune diseases where CD198 is involved. These include asthma, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, and multiple sclerosis. In these diseases, CD198 is known to play a role in the recruitment and activation of immune cells, leading to tissue damage and inflammation. By targeting CD198, Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811) can potentially reduce these pathological processes and provide therapeutic benefits to patients.

Conclusion

In summary, Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811) is a potent and specific antibody targeting CD198, a key receptor involved in immune cell migration and activation. Its unique structure and activity make it a promising therapeutic candidate for various inflammatory and autoimmune diseases. Further research and clinical trials are needed to fully explore the potential of this antibody in improving the treatment of these diseases.